175 related articles for article (PubMed ID: 30008942)
1. Overexpression of Napsin A resensitizes drug-resistant lung cancer A549 cells to gefitinib by inhibiting EMT.
Zhou L; Lv X; Yang J; Zhu Y; Wang Z; Xu T
Oncol Lett; 2018 Aug; 16(2):2533-2538. PubMed ID: 30008942
[TBL] [Abstract][Full Text] [Related]
2. Delivery of gefitinib in synergism with thymoquinone
Upadhyay P; Ghosh A; Basu A; Pranati PA; Gupta P; Das S; Sarker S; Bhattacharjee M; Bhattacharya S; Ghosh S; Chattopadhyay S; Adhikary A
Biomater Sci; 2021 Dec; 9(24):8285-8312. PubMed ID: 34766965
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of epithelial-mesenchymal transition in A549 cell by transfected Napsin A.
Zheng JX; Guan SH; Xu Q; Liu JZ; Song P
Chin Med J (Engl); 2012 Aug; 125(15):2734-40. PubMed ID: 22931983
[TBL] [Abstract][Full Text] [Related]
4. The long non-coding RNA, GAS5, enhances gefitinib-induced cell death in innate EGFR tyrosine kinase inhibitor-resistant lung adenocarcinoma cells with wide-type EGFR via downregulation of the IGF-1R expression.
Dong S; Qu X; Li W; Zhong X; Li P; Yang S; Chen X; Shao M; Zhang L
J Hematol Oncol; 2015 Apr; 8():43. PubMed ID: 25925741
[TBL] [Abstract][Full Text] [Related]
5. Napsin A is negatively associated with EMT‑mediated EGFR‑TKI resistance in lung cancer cells.
Zhou L; Lv X; Yang J; Zhu Y; Wang Z; Xu T
Mol Med Rep; 2018 Aug; 18(2):1247-1252. PubMed ID: 29845258
[TBL] [Abstract][Full Text] [Related]
6. Metformin sensitizes EGFR-TKI-resistant human lung cancer cells in vitro and in vivo through inhibition of IL-6 signaling and EMT reversal.
Li L; Han R; Xiao H; Lin C; Wang Y; Liu H; Li K; Chen H; Sun F; Yang Z; Jiang J; He Y
Clin Cancer Res; 2014 May; 20(10):2714-26. PubMed ID: 24644001
[TBL] [Abstract][Full Text] [Related]
7. Astragalus polysaccharides reverse gefitinib resistance by inhibiting mesenchymal transformation in lung adenocarcinoma cells.
Wei J; Li Y; Xu B; Yu J
Am J Transl Res; 2020; 12(5):1640-1657. PubMed ID: 32509166
[TBL] [Abstract][Full Text] [Related]
8. Cucurbitacin B inhibits TGF-β1-induced epithelial-mesenchymal transition (EMT) in NSCLC through regulating ROS and PI3K/Akt/mTOR pathways.
Yuan R; Fan Q; Liang X; Han S; He J; Wang QQ; Gao H; Feng Y; Yang S
Chin Med; 2022 Feb; 17(1):24. PubMed ID: 35183200
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic silencing of miR-483-3p promotes acquired gefitinib resistance and EMT in EGFR-mutant NSCLC by targeting integrin β3.
Yue J; Lv D; Wang C; Li L; Zhao Q; Chen H; Xu L
Oncogene; 2018 Aug; 37(31):4300-4312. PubMed ID: 29717264
[TBL] [Abstract][Full Text] [Related]
10. Epithelial to mesenchymal transition derived from repeated exposure to gefitinib determines the sensitivity to EGFR inhibitors in A549, a non-small cell lung cancer cell line.
Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Kim CH; Lee JC
Lung Cancer; 2009 Feb; 63(2):219-26. PubMed ID: 18599154
[TBL] [Abstract][Full Text] [Related]
11. Pedunculoside inhibits epithelial-mesenchymal transition and overcomes Gefitinib-resistant non-small cell lung cancer through regulating MAPK and Nrf2 pathways.
Fan Q; Liang X; Xu Z; Li S; Han S; Xiao Y; Xu Q; Yuan R; Yang S; Gao H
Phytomedicine; 2023 Jul; 116():154884. PubMed ID: 37209605
[TBL] [Abstract][Full Text] [Related]
12. DCLK1 Drives EGFR-TKI-Acquired Resistance in Lung Adenocarcinoma by Remodeling the Epithelial-Mesenchymal Transition Status.
Yan R; Huang X; Liu H; Xiao Z; Liu J; An G; Ge Y
Biomedicines; 2023 May; 11(5):. PubMed ID: 37239162
[TBL] [Abstract][Full Text] [Related]
13. Lentivirus-mediated silencing of CNTN1 enhances gefitinib sensitivity by reversing epithelial-mesenchymal transition in lung adenocarcinoma A549 cells.
Hu CS; Huang JH; Yang DL; Xu C; Xu ZG; Tan HB; Chen ZZ
Oncol Lett; 2021 Jun; 21(6):433. PubMed ID: 33868471
[TBL] [Abstract][Full Text] [Related]
14. Activation of Notch-1 enhances epithelial-mesenchymal transition in gefitinib-acquired resistant lung cancer cells.
Xie M; Zhang L; He CS; Xu F; Liu JL; Hu ZH; Zhao LP; Tian Y
J Cell Biochem; 2012 May; 113(5):1501-13. PubMed ID: 22173954
[TBL] [Abstract][Full Text] [Related]
15. Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo.
Xie M; He CS; Wei SH; Zhang L
Eur J Cancer; 2013 Nov; 49(16):3559-72. PubMed ID: 23916913
[TBL] [Abstract][Full Text] [Related]
16. Blockade of Hedgehog Signaling Synergistically Increases Sensitivity to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small-Cell Lung Cancer Cell Lines.
Bai XY; Zhang XC; Yang SQ; An SJ; Chen ZH; Su J; Xie Z; Gou LY; Wu YL
PLoS One; 2016; 11(3):e0149370. PubMed ID: 26943330
[TBL] [Abstract][Full Text] [Related]
17. Triptolide inhibits epithelial‑mesenchymal transition and induces apoptosis in gefitinib‑resistant lung cancer cells.
Li F; Cui H; Jin X; Gong X; Wang W; Wang J
Oncol Rep; 2020 May; 43(5):1569-1579. PubMed ID: 32323848
[TBL] [Abstract][Full Text] [Related]
18. Leptomycin B reduces primary and acquired resistance of gefitinib in lung cancer cells.
Liu Z; Gao W
Toxicol Appl Pharmacol; 2017 Nov; 335():16-27. PubMed ID: 28942004
[TBL] [Abstract][Full Text] [Related]
19. Implication of epithelial-mesenchymal transition in IGF1R-induced resistance to EGFR-TKIs in advanced non-small cell lung cancer.
Zhou J; Wang J; Zeng Y; Zhang X; Hu Q; Zheng J; Chen B; Xie B; Zhang WM
Oncotarget; 2015 Dec; 6(42):44332-45. PubMed ID: 26554308
[TBL] [Abstract][Full Text] [Related]
20. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling.
Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H
Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
